Research programme: STAT3 inhibitors - GLG PharmaAlternative Names: GLG-302; GLG-805
Latest Information Update: 16 Jul 2016
At a glance
- Originator Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute
- Developer GLG Pharma
- Class Small molecules
- Mechanism of Action STAT3 transcription factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
- No development reported Cancer; Kidney disorders